Supect® (Radotinib HCl) Completes Phase 3 Trials

Supect® (Radotinib HCl) Completes Phase 3 Trials. The trials began in August 2011 targeting 240 patients and in a multinational study onducted in South Korea, Thailand, Indonesia, and the Philippines. Supect is the first leukemia drug to be developed in Asia.

Supect is a second generation tyrosine kinase inhibitor approved in South Korea for the treatment of patients with Philadelphia positive chronic myeloid leukemia (Ph+ CML) without optimal response and/or tolerance to other Bcr-Abl tyrosine kinase inhibitors.

Supect-Radotinib-Packaging